Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(3):157; doi:10.1093/jnci/djn008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Sorafenib Targets Mutant FLT3 in Acute Myelogenous Leukemia

The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concentrations in acute myeloid leukemia (AML) cell lines that harbor internal tandem duplication (ITD) mutations in a section of the Fms-like tyrosine kinase 3 (FLT3) gene than in those with wild-type FLT3. Zhang et al. (p. 184) examined the anti-leukemic activity of sorafenib in mouse AML cell lines that expressed mutant or wild-type FLT3, human AML cells, a mouse leukemia xenograft model, and 16 AML patients with known FLT3 gene mutation status who were . . . [Full Text of this Article]

Endogenous Sex Hormones and Prostate Cancer Risk

Surgeon and Patient Attributes and Radiotherapy for Breast Cancer

Ki-67 Expression and Response to Breast Cancer Adjuvant Therapy

Personality Factors and Risk of Breast Cancer

ER Results from Pathology versus Central Laboratory


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Comparison of Estrogen Receptor Results From Pathology Reports With Results From Central Laboratory Testing
Laura C. Collins, Jonathan D. Marotti, Heather J. Baer, and Rulla M. Tamimi
J Natl Cancer Inst 2008 100: 218-221. [Abstract] [Full Text] [PDF]

Personality Factors and Breast Cancer Risk: A 13-Year Follow-up
Eveline M. A. Bleiker, Jan H. C. L. Hendriks, Johannes D. M. Otten, André L. M. Verbeek, and Henk M. van der Ploeg
J Natl Cancer Inst 2008 100: 213-218. [Abstract] [Full Text] [PDF]

Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
Giuseppe Viale, Meredith M. Regan, Mauro G. Mastropasqua, Fausto Maffini, Eugenio Maiorano, Marco Colleoni, Karen N. Price, Rastko Golouh, Tiziana Perin, R. W. Brown, Anikó Kovács, Komala Pillay, Christian Öhlschlegel, Barry A. Gusterson, Monica Castiglione-Gertsch, Richard D. Gelber, Aron Goldhirsch, and Alan S. Coates On the behalf of the International Breast Cancer Study Group
J Natl Cancer Inst 2008 100: 207-212. [Abstract] [Full Text] [PDF]

Surgeon Characteristics and Receipt of Adjuvant Radiotherapy in Women With Breast Cancer
Dawn L. Hershman, Donna Buono, Russell B. McBride, Wei Yann Tsai, Kathy Ann Joseph, Victor R. Grann, and Judith S. Jacobson
J Natl Cancer Inst 2008 100: 199-206. [Abstract] [Full Text] [PDF]

Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Endogenous Hormones and Prostate Cancer Collaborative Group
J Natl Cancer Inst 2008 100: 170-183. [Abstract] [Full Text] [PDF]

Improving Outcomes for Patients With Hormone Receptor–Positive Breast Cancer: Back to the Drawing Board
Matthew J. Ellis
J Natl Cancer Inst 2008 100: 159-161. [Extract] [Full Text] [PDF]

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
Weiguo Zhang, Marina Konopleva, Yue-xi Shi, Teresa McQueen, David Harris, Xiaoyang Ling, Zeev Estrov, Alfonso Quintás-Cardama, Donald Small, Jorge Cortes, and Michael Andreeff
J Natl Cancer Inst 2008 100: 184-198. [Abstract] [Full Text] [PDF]

Getting Over Testosterone: Postulating a Fresh Start for Etiologic Studies of Prostate Cancer
William R. Carpenter, Whitney R. Robinson, and Paul A. Godley
J Natl Cancer Inst 2008 100: 158-159. [Extract] [Full Text] [PDF]